LVTX PE Ratio & Valuation,Is LVTX Overvalued

LVTX Relative Valuation

LVTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LVTX is overvalued; if below, it's undervalued.

Historical Valuation

LAVA Therapeutics NV (LVTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.01. The fair price of LAVA Therapeutics NV (LVTX) is between -- to -- according to relative valuation methord.

Relative Value

Fair Zone

-----

Current Price：1.77

Fair

-2.08

0.00

EV/EBITDA

LAVA Therapeutics NV. (LVTX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.30. The thresholds are as follows: Strongly Undervalued below -3.49, Undervalued between -3.49 and -1.90, Fairly Valued between 1.29 and -1.90, Overvalued between 1.29 and 2.88, and Strongly Overvalued above 2.88. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.06

EV/EBIT

LAVA Therapeutics NV. (LVTX) has a current EV/EBIT of 0.06. The 5-year average EV/EBIT is 0.22. The thresholds are as follows: Strongly Undervalued below -3.04, Undervalued between -3.04 and -1.41, Fairly Valued between 1.85 and -1.41, Overvalued between 1.85 and 3.48, and Strongly Overvalued above 3.48. The current Forward EV/EBIT of 0.06 falls within the Historic Trend Line -Fairly Valued range.

0.00

LAVA Therapeutics NV. (LVTX) has a current PS of 0.00. The 5-year average PS is 97.95. The thresholds are as follows: Strongly Undervalued below -310.67, Undervalued between -310.67 and -106.36, Fairly Valued between 302.26 and -106.36, Overvalued between 302.26 and 506.58, and Strongly Overvalued above 506.58. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

LAVA Therapeutics NV. (LVTX) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.83. The thresholds are as follows: Strongly Undervalued below -19.03, Undervalued between -19.03 and -9.10, Fairly Valued between 10.75 and -9.10, Overvalued between 10.75 and 20.68, and Strongly Overvalued above 20.68. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.19

P/FCF

LAVA Therapeutics NV. (LVTX) has a current P/FCF of -1.19. The 5-year average P/FCF is -2.16. The thresholds are as follows: Strongly Undervalued below -5.40, Undervalued between -5.40 and -3.78, Fairly Valued between -0.53 and -3.78, Overvalued between -0.53 and 1.09, and Strongly Overvalued above 1.09. The current Forward P/FCF of -1.19 falls within the Historic Trend Line -Fairly Valued range.

LAVA Therapeutics NV (LVTX) has a current Price-to-Book (P/B) ratio of 3.61. Compared to its 3-year average P/B ratio of 1.18 , the current P/B ratio is approximately 206.02% higher. Relative to its 5-year average P/B ratio of 1.22, the current P/B ratio is about 195.54% higher. LAVA Therapeutics NV (LVTX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -45.21%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -37.64% , the current FCF yield is about -100.00% lower.

3.61

P/B

Median3y

1.18

Median5y

1.22

-64.60

FCF Yield

Median3y

-45.21

Median5y

-37.64

Competitors Valuation Multiple

The average P/S ratio for LVTX's competitors is 0.83, providing a benchmark for relative valuation. LAVA Therapeutics NV Corp (LVTX) exhibits a P/S ratio of , which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of LVTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of LVTX in the past 1 year is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is LAVA Therapeutics NV (LVTX) currently overvalued or undervalued?

What is LAVA Therapeutics NV (LVTX) fair value?

LVTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of LAVA Therapeutics NV (LVTX) is between to according to relative valuation methord.

How does LVTX's valuation metrics compare to the industry average?

The average P/S ratio for LVTX's competitors is 0.83, providing a benchmark for relative valuation. LAVA Therapeutics NV Corp (LVTX) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for LAVA Therapeutics NV (LVTX) as of Dec 15 2025?

As of Dec 15 2025, LAVA Therapeutics NV (LVTX) has a P/B ratio of 3.61. This indicates that the market values LVTX at 3.61 times its book value.

What is the current FCF Yield for LAVA Therapeutics NV (LVTX) as of Dec 15 2025?

As of Dec 15 2025, LAVA Therapeutics NV (LVTX) has a FCF Yield of 0.00%. This means that for every dollar of LAVA Therapeutics NV’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for LAVA Therapeutics NV (LVTX) as of Dec 15 2025?

As of Dec 15 2025, LAVA Therapeutics NV (LVTX) has a Forward P/E ratio of -2.08. This means the market is willing to pay $-2.08 for every dollar of LAVA Therapeutics NV’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for LAVA Therapeutics NV (LVTX) as of Dec 15 2025?

As of Dec 15 2025, LAVA Therapeutics NV (LVTX) has a Forward P/S ratio of 0.00. This means the market is valuing LVTX at $0.00 for every dollar of expected revenue over the next 12 months.

LVTX Valuation

LVTX Valuation

LVTX Relative Valuation

Historical Valuation

Competitors Valuation Multiple

Performance Decomposition

People Also Watch

Frequently Asked Questions

Is LAVA Therapeutics NV (LVTX) currently overvalued or undervalued?

What is LAVA Therapeutics NV (LVTX) fair value?

How does LVTX's valuation metrics compare to the industry average?

What is the current P/B ratio for LAVA Therapeutics NV (LVTX) as of Dec 15 2025?

What is the current FCF Yield for LAVA Therapeutics NV (LVTX) as of Dec 15 2025?

What is the current Forward P/E ratio for LAVA Therapeutics NV (LVTX) as of Dec 15 2025?

What is the current Forward P/S ratio for LAVA Therapeutics NV (LVTX) as of Dec 15 2025?